Click Here to Go Directly to the Story
Register/Subscribe
Home




U.S. EDITION
Full Table of Contents
 Cover Story
Up Front
Readers Report
Corrections & Clarifications
Books
Technology & You
Economic Viewpoint
Economic Trends
Industry Insider
Business Outlook

News: Analysis & Commentary
In Business This Week
Washington Outlook
International Business
International Outlook
Government
Information Technology
Social Issues
The Corporation
People

Sports Business
Finance
Science & Technology
Developments to Watch
BusinessWeek Investor
BusinessWeek Lifestyle
The Barker Portfolio
Inside Wall Street
Figures of the Week
Editorials


E.BIZ SUPPLEMENT March 18 Table of Contents

INTERNATIONAL EDITIONS
International -- Readers Report
International -- Asian Business
International -- European Business
International -- Finance
International -- Int'l Figures of the Week
ONLINE FEATURES Book Reviews BW Video Columnists Interactive Gallery Newsletters Past Covers Philanthropy Podcasts Special Reports BLOGS Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Economics Unbound Eye on Asia Fine On Media Green Biz Hot Property Investing Insights Management IQ NEXT: Innovation NussbaumOnDesign Tech Beat Working Parents TECHNOLOGY J.D. Power Ratings Product Reviews Tech Stats Wildstrom: Tech Maven AUTOS Home Page Auto Reviews Classic Cars Car Care & Safety Hybrids INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads


MARCH 18, 2002

Corrections & Clarifications

  STORY TOOLS
Printer-Friendly Version
E-Mail This Story

On This Page
"New drugs: Why so many delays?" (Science & Technology, Mar. 11, 2002)

"New drugs: Why so many delays?" (Science & Technology, Mar. 11, 2002)

 "New drugs: Why so many delays?" (Science & Technology, Mar. 11) said Chiron Corp.'s HIV blood test, Procleix, was pending Food & Drug Administration approval. The drug was approved on Feb. 28, a year after the application was filed and a day after BusinessWeek's issue went to press.



Back to Top


TODAY'S MOST POPULAR STORIES

  1. Why Google Is Buying AdMob
  2. Kraft: Is Cadbury the Missing Global Ingredient?
  3. The Global Innovation Migration
  4. The Accidental Hero
  5. Stock Picks: McDonald's, Northrop Grumman, Disney

Get Free RSS Feed >>
  MARKET INFO
DJIA 10224.22 -2.72
S&P 500 1091.61 -1.47
Nasdaq 2148.12 -5.94

Portfolio Service Update

Stock Lookup

Enter name or ticker



Copyright 2002 , by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use | Privacy Policy

Media Kit | Special Sections | MarketPlace | Knowledge Centers
McGraw-Hill Cos.